PharmaDepth

Company profile

Merck & Co., Inc.

NYSE:MRKBiotechnology: Pharmaceutical Preparations

Drug pipeline (179)

AssetStageRevenueTrialsStatus
PEMBROLIZUMABphase3$8.4BQ2 2026263active
Sugammadex sodiumapproved$497.0MQ2 20260—
Sitagliptin Phosphateapproved$429.0M*Q2 202627approved
Letermovirapproved$295.0MQ2 20267approved
Belzutifanapproved$271.0MQ2 202629approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (2223)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00543465phase2terminated2004-08-012004-11-01Merck Sharp & Dohme LLC12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)
NCT00090155phase3completed2003-09-262004-11-24Merck Sharp & Dohme LLC2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
NCT00090246phase3completed2004-05-132005-04-06Merck Sharp & Dohme LLC2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
NCT01028391phase3completed2007-09-012009-01-01Merck Sharp & Dohme LLC30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
NCT00761735phase3completed2007-07-012013-01-01Merck Sharp & Dohme LLC5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

FDA applications (152)

ApplicationTypeApplicantProducts
ANDA 062756ANDAMERCK AND CO INC
ANDA 080778ANDAMERCK AND CO INC
BLA 020328BLAOrganon USA Inc., a subsidiary of Merck & Co., Inc.
BLA 020580BLAOrganon USA Inc., a subsidiary of Merck & Co., Inc.
BLA 020582BLAOrganon USA Inc., a subsidiary of Merck & Co., Inc.